[1]
Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: A target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302: 1219-30.
[2]
Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 2013; 10: 125-34.
[3]
Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides 2011; 32: 2141-50.
[4]
Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: Novel therapeutic targets. Nat Rev Cardiol 2014; 11: 413-26.
[5]
De Kloet AD, Steckelings UM, Sumners C. Protective angiotensin type 2 receptors in the brain and hypertension. Curr Hypertens Rep 2017; 19: 46.
[6]
Mendoza A, Lazartigues E. The compensatory renin-angiotensin system in the central regulation of arterial pressure: New avenues and new challenges. Ther Adv Cardiovasc Dis 2015; 9: 201-8.
[7]
Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-63.
[8]
Gironacci M, Cerniello FM, Longo Carbajosa NA, Goldstein J, Cerrato BD. Protective axis of the renin-angiotensin system in the brain. Clin Sci (Lond) 2014; 127: 295-306.
[9]
Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: The axis of good. Am J Physiol Regul Integr Comp Physiol 2011; 300: 804-17.
[10]
Doobay M, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 292: 373-81.
[11]
Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 2011; 92: 401-8.
[12]
Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006; 290: 420-6.
[13]
Feng Y, Xia H, Cai Y, et al. Brain-selective overexpression of human Angiotensin converting enzyme type 2 attenuates neurogenic hypertension. Circ Res 2010; 106: 373-82.
[14]
Gurley SB, Allred A, Le TH, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116: 2218-25.
[15]
Feng Y, Yue X, Xia H, et al. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res 2008; 102: 729-36.
[16]
Xia H, Suda S, Bindom S, et al. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One 2011; 6: e22682.
[17]
Oliveira DR, Santos RA, Santos GF, Khosla M, Campagnole-Santos MJ. Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension 1996; 27: 1284-90.
[18]
Lu J, Jiang T, Wu L, et al. The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. Neuropeptides 2013; 47: 289-95.
[19]
Jiang T, Gao L, Shi J, Lu J, Wang Y, Zhang Y. Angiotensin-(1-7) modulates renin-angiotensin system associated with reducing oxidative stress and attenuating neuronal apoptosis in the brain of hypertensive rats. Pharmacol Res 2013; 67: 84-9.
[20]
Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin (1-7). Hypertension 2003; 42: 574-9.
[21]
Zhang F, Hu Y, Xu Q, Ye S. Different effects of angiotensin II and angiotensin (1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 2010; 5: e12323.
[22]
Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: Prevention of angiotensin II-dependent hypertension. Hypertension 2010; 55: 90-8.
[23]
Kangussu LM, Guimaraes PS, Nadu AP, Melo MB, Santos RA, Campagnole-Santos MJ. Activation of angiotensin-(1-7)/Mas axis in the brain lowers blood pressure and attenuates cardiac remodeling in hypertensive transgenic (mRen2)27 rats. Neuropharmacology 2015; 97: 58-66.
[24]
Bennion D, Haltigan E, Regenhardt RW, Steckelings UM, Sumners C. Neuroprotective mechanisms of the ACE2-angiotensin-(1-7) - Mas axis in stroke. Curr Hypertens Rep 2015; 17: 3.
[25]
Chen J, Zhao Y, Chen S, et al. Neuronal over-expression of ACE2 protects brain from ischemia-induced damage. Neuropharmacology 2014; 79: 550-8.
[26]
Chang AY, Li FC, Huang CW, et al. Interplay between brain stem angiotensins and monocyte chemoattractant protein-1 as a novel mechanism for pressor response after ischemic stroke. Neurobiol Dis 2014; 71: 292-304.
[27]
Chen J, Zhao Y, Chen S, et al. Neuronal over-expression of ACE2 protects brain from ischemia-induced damage. Neuropharmacology 2014; 79: 550-8.
[28]
Lu J, Zhang Y, Shi J. Effects of intracerebroventricular infusion of angiotensin(1-7) on bradykinin formation and the kinin receptor expression after focal cerebral ischemia-reperfusion in rats. Brain Res 2008; 1219: 127-35.
[29]
Kluskens LD, Nelemans SA, Rink R, et al. Angiotensin-(1-7) with thioether bridge: An angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther 2009; 328: 849-54.
[30]
Durik M, van Veghel R, Kuipers A, et al. The effect of the thioether-bridged, stabilized angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. Int J Hypertens 2012; 2012: 536426.
[31]
Marques FD, Ferreira AJ, Sinisterra RD, et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011; 57: 477-83.
[32]
Simões e Silva AC. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013; 169: 477-92.
[33]
Dai SY, Peng W, Zhang YP, Li JD, Shen Y, Sun XF. Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats. J Neuroinflammation 2015; 12: 47.
[34]
Jiang F, Yang J, Zhang Y, et al. Angiotensin converting enzyme 2 and angiotensin 1-7: Novel therapeutic targets. Nat Rev Cardiol 214(11): 413-4.
[35]
De Kloet AD, Steckelings UM, Sumners C. Protective angiotensin type 2 receptors in the brain and hypertension. Curr Hypertens Rep 2017; 19: 46.
[36]
Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 2011; 121: 297-303.
[37]
Villela D, Leonhardt J, Patel N, et al. Angiotensin AT2-receptor and receptor Mas: A complex liaison. Clin Sci (Lond) 2015; 128: 227-3.
[38]
Hrenak J, Paulis L, Simko F. Angiotensin A/alamandine/MrgD axis: Another clue to understanding cardiovascular pathophysiology. Int J Mol Sci 2016; 17: 1098.
[39]
Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 2006; 48: 316-22.
[40]
Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas knockout mice. J Cardiovasc Pharmacol 2005; 46: 274-9.
[41]
Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32: 2143-52.
[42]
Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high, middle and low-income countries. JAMA 2013; 310: 959-68.
[43]
Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: A serial cross-sectional study from 1994 to 2011. Lancet 2014; 383: 1912-9.
[44]
Tocci G, Rosei EA, Ambrosioni E, et al. Blood pressure control in Italy: Analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens 2012; 30: 1065-74.
45
4
2